#None #Securities Law #Faruqi & Faruqi #REGENXBIO

Important Investor Notice on REGENXBIO

Faruqi & Faruqi, LLP, a prominent national securities law firm, is actively investigating potential claims against REGENXBIO Inc. (NASDAQ: RGNX). Investors who acquired securities of REGENXBIO between February 9, 2022, and January 27, 2026, should take note of the upcoming deadline on April 14, 2026, to seek the role of lead plaintiff in an ongoing federal securities class action.

Background of the Case

The investigation follows a significant announcement made by REGENXBIO on January 28, 2026, when the U.S. Food and Drug Administration (FDA) placed a clinical hold on their gene therapy trial, RGX-111, aimed at treating mucopolysaccharidosis type I (MPS I), known as Hurler syndrome. This hold came after reports of a serious adverse event involving a neoplasm in a participant. Moreover, the FDA raised similar concerns about RGX-121, which targets mucopolysaccharidosis type II (MPS II), or Hunter syndrome, due to overlapping study parameters.

Following these disclosures, REGENXBIO’s stock plummeted by $2.40, representing a 17.9% decrease and closing at $11.01 per share. This decline highlights the market's reaction to fears surrounding the efficacy and safety of the company's gene therapy products, raising questions about the information that was disclosed to investors.

Who Should Act?

Investors who suffered losses in these securities are encouraged to contact Faruqi & Faruqi immediately. James (Josh) Wilson, a partner at the firm, is leading this investigation. He emphasizes that it's crucial for investors to understand their legal rights and options following the sudden downturn in stock value. Interested parties can reach him directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

The role of a lead plaintiff involves overseeing the litigation process and representing the interests of the class members. Members of the putative class can choose to apply for this position or remain absent entirely without affecting their potential recovery in the case.

Encouragement for Whistleblowers

Faruqi & Faruqi also extends an invitation to individuals with insider knowledge about REGENXBIO's practices to come forward. This includes former employees, shareholders, and whistleblowers who can provide critical information that may support the claims against the company.

Conclusion

As the April 14 deadline approaches, affected investors are strongly advised to explore their legal options. The law firm has a long-standing history, having successfully recovered substantial amounts for investors since its establishment in 1995. For more detailed information regarding this case, inquiries can be directed to www.faruqilaw.com/RGNX.

Stay informed and proactive regarding your investment in REGENXBIO by reaching out to Faruqi & Faruqi to protect your rights.